Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Capecitabine 35 Oxaliplatin 32 Fluorouracil 29 Leucovorin 26 Irinotecan 22 Bevacizumab 19 Cetuximab 17 Radiotherapy 16 Radiation 11 Surgical Procedures, Operative 6 Radiotherapy, Intensity-Modulated 5 Gene Expression Profiling 5 Chemotherapy, Adjuvant 5 Celecoxib 5 Neoadjuvant Therapy 4 Immunohistochemistry 4 Biopsy 4 Amplified Fragment Length Polymorphism Analysis 4 cediranib 3 Reverse Transcriptase Polymerase Chain Reaction 3 Receptor Protein-Tyrosine Kinases 3 Folfox protocol 3 Drug Therapy 3 Cisplatin 3 sargramostim 2 regorafenib 2 pembrolizumab 2 fludarabine phosphate 2 aldesleukin 2 Surveys and Questionnaires 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Rectal Neoplasms × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡